Literature DB >> 8358949

Osteopetrosis. The pharmaco-physiologic basis of therapy.

L L Key1, W L Ries.   

Abstract

Medical treatments of osteopetrosis have attempted to improve hematologic function, reduce the osteosclerotic condition, and/or improve immune function. Prednisone therapy has improved hematologic function in some patients, but has not resulted in a reduction in bone mass. Calcium deficient diets have limited further sclerosis in some patients. High-dose calcitriol and parathormone infusions have stimulated osteoclastic activity. In some patients, high-dose calcitriol has resulted in clinical improvement. Newer treatments, such as interferon gamma and macrophage colony stimulating factor, may alter the osteoclastic and immune defects by stimulating cellular formation and function. These therapies, alone or in combination, ameliorate but do not cure the osteopetrotic condition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358949

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Interferon Gamma-1b Does Not Increase Markers of Bone Resorption in Autosomal Dominant Osteopetrosis.

Authors:  Erik A Imel; Ziyue Liu; Dena Acton; Melissa Coffman; Netsanet Gebregziabher; Yan Tong; Michael J Econs
Journal:  J Bone Miner Res       Date:  2019-05-13       Impact factor: 6.741

2.  Superoxide generation in transformed B-lymphocytes from patients with severe, malignant osteopetrosis.

Authors:  S Yang; W L Ries; L L Key
Journal:  Mol Cell Biochem       Date:  1999-09       Impact factor: 3.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.